Akcea Therapeutics, Inc. AKCA Cash Flow

Akcea therapeutics, inc. (AKCA)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17
Operating activities:
Net (loss) income
-29,265	40,772	-112,191	-144,284	-169,007	-225,821	-174,972	-129,018	-87,330	-121,559	0	0	0
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation
794	789	792	653	487	307	135	106	106	108	0	0	0
Amortization of right-of-use operating lease assets
838	942	0	0	0	-	-	-	-	-	-	-	-
Amortization of intangibles
5,879	5,863	6,440	5,708	4,286	2,870	846	130	120	120	0	0	0
Amortization of premium/discount on investment securities, net
-102	438	690	665	401	23	-384	-568	-624	-499	0	0	0
Non-cash interest expense for line of credit with Ionis Pharmaceuticals, Inc.
-	-	-	-	-	-	-	-	-	1,731	0	0	0
Non-cash sublicensing expense
-	200,000	0	0	0	-	-	-	-	-	-	-	-
Stock-based compensation expense
25,834	37,112	42,502	58,696	56,458	44,282	36,964	28,926	20,743	17,539	0	0	0
Changes in operating assets and liabilities:
Accounts receivable
404	5,899	10,017	5,898	10,269	-816	136	3,295	0	5,413	0	0	0
Other current and long-term assets
6,653	5,316	1,832	7,371	5,681	8,680	7,705	2,810	4,172	1,761	0	0	0
Inventories
6,655	4,545	0	0	0	-	-	-	-	-	-	-	-
Payable to Ionis Pharmaceuticals, Inc.
-	-	-	-	-	-	-	-	-	-	-	-	0
Accounts payable
4,219	-610	3,030	5,229	3,574	8,444	1,308	3,029	2,561	1,905	0	0	0
Receivable from Ionis Pharmaceuticals, Inc.
-4,653	22,132	24,219	35,057	35,010	-4,527	82,435	43,724	39,368	43,385	0	0	0
Income tax receivable
0	-	-	-	-	-	-	-	-	-	-	-	-
Accrued compensation
0	-	-	-	0	-	-	-	-	-	-	-	-
Accrued compensation
-	-	-	-	-	4,500	6,541	3,296	2,926	1,578	0	0	0
Deferred rent
-	-	-	-	-	-	-	-	-	-	0	0	0
Accrued liabilities
-2,211	-1,877	-5,375	-7,428	4,650	8,420	17,427	23,412	12,074	6,572	0	0	0
Income taxes payable
1	716	85	11	-659	-540	-813	1,069	1,861	1,789	0	0	0
Deferred revenue
-22,432	-26,623	-23,971	-25,722	-33,461	-41,905	-52,729	-21,641	-45,576	70,693	0	0	0
Net cash (used in) provided by operating activities
101,128	223,825	-53,631	-81,753	-107,533	-202,888	-158,684	-113,510	-79,123	-36,190	0	0	0
Investing activities:
Purchases of short-term investments
328,040	186,988	143,554	193,304	140,847	136,895	187,289	262,365	261,818	301,377	0	0	0
Proceeds from maturity of short-term investments
191,123	197,012	225,278	213,866	231,801	208,559	194,370	175,694	132,475	98,778	0	0	0
Purchases of property, plant and equipment
774	1,596	0	0	0	-	-	-	-	-	-	-	-
Net cash (used in) provided by investing activities
-137,691	8,428	79,303	18,059	88,804	70,545	6,965	-86,685	-129,352	-202,608	0	0	0
Financing activities:
Proceeds from exercise of common stock options and employee stock purchase plan issuances
8,931	11,574	11,007	11,091	9,827	6,963	0	0	0	-	0	0	0
Distribution to Ionis Pharmaceuticals, Inc.
-	13,492	13,492	13,492	21,284	7,792	0	0	0	-	-	-	-
Payments of tax withholdings related to exercise of employee stock awards
0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from line of credit from Ionis Pharmaceuticals, Inc.
-	-	-	-	-	-	-	-	-	106,000	0	0	0
Offering costs paid
-	-	-	-	-	-	-	-	-	2,037	0	0	0
Net cash provided by (used in) financing activities
-1,160	-11,933	-12,488	-2,839	152,203	162,831	160,017	344,019	200,584	289,401	0	0	0
Effect of exchange rates on cash
16	92	-61	-73	30	-17	-74	-45	-60	-93	0	0	0
Net (decrease) increase in cash and cash equivalents
-37,707	220,412	13,123	-66,606	133,504	30,471	8,224	143,779	-7,951	50,510	0	0	0
Supplemental disclosures of non-cash financing activities:
Unpaid deferred offering costs
-	-	-	-	-	-	-	0	0	-	0	0	0
Ionis [Member]
Purchase of property, plant and equipment included in payable to Ionis Pharmaceuticals, Inc.
0	-	-	-	-	-	-	-	-	-	-	-	-